Kymera Therapeutics, Inc. (KYMR) - Stock Analysis
Last updated: Mar 8, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Biotech momentum with nearâterm event: KYMR is up ~28% over 21 days with notable institutional accumulation (Baker Brothers, Rock Springs) and has its FY2025 results/earnings call on 2026â02â26; strong cash runway into 2028â2029 and positive early biomarker data support a speculative upside move if management reinforces timelines and clinical strategy.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Acute operating losses ⢠Financingâdependent cash flow KYMR has a very strong, lowâleverage balance sheet and ample cash but is loss-making with minimal revenue, negative free cash flow, and heavy reliance on external financing to fund outsized R&D, posing acute profitability and cashâflow risk.
Price Behavior
Key Price Behavior Insights: ⢠Below last-month SMA ⢠Support low-$80s ⢠Resistance $90â95 Support Level: $82â83, deeper $79, $75.94 Resistance Level: $90â95 (major at $95.03) KYMR has rolled over short-termâtrading below the last month SMA after a sharp pullback from a $95.03 high, with near-term support in the low $80s (deeper at $79/$75.94), resistance at $90â95, and a neutral RSI (~52).
Sentiment & News
Key News Insights: ⢠R&D acceleration ⢠Strong cash runway ⢠Mixed stock activity Kymera widened Q4 losses and missed revenue as R&D spending ramped, but a roughly $1.6B cash cushion, broad analyst Buy consensus and institutional buying underpin progress toward KT-621 and KT-579 catalysts despite mixed insider activity.
AI Summary
Kymera's upsized ~$1.6B balance sheet shifts the thesis from financing survival to clinical execution riskâinvestors should now prioritize KTâ621 midâstage readouts (BROADEN2/BREADTH) and KTâ579 Phaseâ1 outcomes, monitor quarterly burn and milestone probabilities, because clean, placeboâseparating efficacy would materially reârate the stock while failed readouts could still trigger dilution despite the strong cash cushion.
Description
Kymera Therapeutics develops small-molecule drugs that induce selective removal of disease-causing proteins by engaging the bodyâs native protein degradation pathways. Its pipeline includes an IRAK4 candidate in Phase I for several immuno-inflammatory conditions and programs targeting MYD88-mutant lymphoma, STAT3-related hematologic and solid tumors as well as autoimmune and fibrotic diseases, and MDM2-driven malignancies. The company was incorporated in 2015 and is based in Watertown, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 25 | Mar 4 | KYMR | Kymera Therapeutics, Inc. | Biotech momentum with nearâterm event: KYMR is up ~28% over 21 days with notable institutional accumulation (Baker Brothers, Rock Springs) and has its FY2025 results/earnings call on 2026â02â26; strong cash runway into 2028â2029 and positive early biomarker data support a speculative upside move if management reinforces timelines and clinical strategy. | Closed | -5.0% |